Shorter TB treatment for drug-sensitive tuberculosis
Part of Infections, Lungs & breathing clinical trials.
This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You weigh between 40 and 90 kg (about 88 to 198 pounds).
- You can produce at least 10 mL of sputum (phlegm) overnight.
- Your TB bacteria are sensitive to the antibiotic rifampin (not resistant).
- You have received no more than 3 days of TB treatment in the past 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether you can take a shorter course of standard treatment for drug-sensitive pulmonary (lung) tuberculosis by using a higher dose of rifampicin. It may help some people finish treatment sooner, while doctors track how well the infection clears.
This trial tests a shorter treatment for TB that is resistant to the drug rifampicin but still sensitive to isoniazid. It may help people finish treatment sooner and with fewer side effects.
This study tests a new tuberculosis drug called TBD09 combined with other TB medicines in people with newly diagnosed, drug-sensitive TB. The goal is to see if this combination works well and is safe.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.
Hear when a new Tuberculosis, Pulmonary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.